News

Centessa Pharmaceuticals Names New CEO Driving Orexin Advancements

Centessa Pharmaceuticals Names New CEO Driving Orexin Advancements

Centessa Pharmaceuticals' Leadership Transition

In a significant step forward for Centessa Pharmaceuticals plc (Nasdaq: CNTA), the company has appointed Dr. Mario Alberto Accardi as its new Chief Executive Officer (CEO), effective January 1, 2026. This transition marks the culmination of a strategic evolution the company is undergoing, moving from a broad R&D focus to specializing in orexin therapies that target neurological and neuropsychiatric disorders.

The New Era Under Dr. Accardi

Dr. Accardi, who is recognized as the founder of Centessa’s Orexin Program, replaces Saurabh Saha, who will now serve as an advisor to the CEO. Francesco De Rubertis, Chair of Centessa’s Board, expressed confidence in Dr. Accardi's capabilities, emphasizing that his deep understanding of orexin biology and visionary approach aligns perfectly with the company’s mission. Dr. Saha's leadership has been pivotal in laying a robust foundation, guiding the company through its formative stages and significant milestones in drug development.

Reflections on Leadership Transition

Dr. Saha shared his thoughts on the leadership change, indicating that the time is right for such a transition as Centessa stands on the brink of a new chapter focusing solely on orexin therapeutics. He acknowledged Dr. Accardi as the right person to lead the company forward, particularly due to his integral role in developing the OX2R agonist program.

Centessa’s Focus on OX2R Agonists

Under Dr. Accardi’s leadership, Centessa aims to capitalize on the growth opportunities presented by OX2R agonists in the neuroscience space. The company’s flagship candidate, ORX750, has shown promising results in treating narcolepsy and idiopathic hypersomnia, with the registrational program slated to start in early 2026. Additionally, Centessa is progressing with other investigational compounds like ORX142 and ORX489, aimed at addressing various neurodegenerative and neuropsychiatric conditions.

Advancing the Orexin Pipeline

Dr. Accardi has a rich background in neuroscience and has previously led Orexia Therapeutics, where he successfully acquired substantial funding and strategically positioned the company for growth before its acquisition by Centessa. His educational qualifications make him well-suited for the CEO role, holding a Postgraduate in Genomic Medicine and a PhD in Biomedical Engineering.

The Promise of Orexin Therapies

Orexins are neuropeptides integral to regulating the sleep-wake cycle, and innovations in this field could address issues such as excessive daytime sleepiness, impaired cognitive function, and various fatigue-related disorders. Centessa is at the forefront of developing these OX2R agonists, exploring their therapeutic potential to transform treatment landscapes for patients battling neurological challenges.

Research & Development Focus

Ongoing clinical trials, including the Phase 2a CRYSTAL-1 study for ORX750, aim to verify the efficacy and safety of Centessa’s drug candidates. The commitment to developing transformative medicines remains strong, with a clear vision for the future enriched by Dr. Accardi's leadership.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals is a clinical-stage pharmaceutical entity dedicated to discovering and bringing to market groundbreaking medicines aimed primarily at neurological disorders. With a promising pipeline centered on orexin therapies, Centessa continues to pave the way for patients in need of effective treatment options. Investors and stakeholders looking for more information can reach out via email or visit Centessa’s official website, where updates about ongoing and future programs can also be found.

Frequently Asked Questions

Who has been appointed as the new CEO of Centessa Pharmaceuticals?

Dr. Mario Alberto Accardi has been appointed as the new CEO of Centessa Pharmaceuticals.

What position does Saurabh Saha take after the leadership change?

Saurabh Saha will remain with the company as an advisor to the CEO following his transition from CEO.

What are some key products Centessa is focusing on?

Centessa is focusing on OX2R agonists, particularly ORX750, ORX142, and ORX489, targeting various neurological and sleep-wake disorders.

What is the purpose of the OX2R agonist program?

The OX2R agonist program is designed to address excessive daytime sleepiness, cognitive deficits, and fatigue associated with several neurological disorders.

How can investors contact Centessa Pharmaceuticals?

Investors can contact Centessa Pharmaceuticals through Kristen K. Sheppard, SVP of Investor Relations, at investors@centessa.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 106

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 156

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 79

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 56

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Xiong'an New Area: People's Priorities Reshape Living Spaces

Updated Category News Views 89

Building a City for the People This here is about prioritizing people over skylines. Xiong'an New Area in Hebei Province is shaping up to be more than just a place on the map; it's an experiment in redefining urban living. Skyscrapers and traffic jams? Not on this menu. Instead, nature paves a graceful dance floor between mid-rise residences. Forget your bustling city...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 221

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 16

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 85

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 88

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 85

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading

Top 5 Most Recently Viewed Articles

Disney Steers Focus Towards Asia's Streaming Landscape Success

Updated Category News Views 192

Disney Enters the Competitive Asian Streaming Market Walt Disney Co (NYSE: DIS) is strategically positioning itself to dominate in the vibrant Asian streaming market. The company's latest initiative involves a significant investment in original Japanese anime, alongside the expansion of its Korean superhero franchise. With this bold move, Disney aims to establish a strong...

Continue Reading
MSSA and GSMA Unite to Expand Mobile Satellite Services

Updated Category News Views 81

Strategic Alliance of MSSA and GSMA The Mobile Satellite Services Association (MSSA) has announced an exciting new partnership with the GSMA, a leading global organization dedicated to mobile operators and the broader mobile ecosystem. This synergy aims to elevate mobile technology to new heights and transform the landscape of mobile satellite communications. Advancing...

Continue Reading
Celebrating Pioneers: 2025 XCEL Summit for Men Highlights Heroes

Updated Category News Views 259

Honoring Leadership at the 2025 XCEL Summit for Men Black Enterprise is excited to showcase the remarkable individuals receiving the prestigious XCEL Awards at the much-anticipated XCEL Summit for Men. This year's celebration promises to be a hallmark event, scheduled for mid-October at the Hyatt Regency Grand Cypress in Orlando. Attendees can expect a magnificent...

Continue Reading
Innovative Trial Launches to Combat Pediatric Leukemia Worldwide

Updated Category News Views 259

Revolutionizing Pediatric Leukemia Treatment The Leukemia & Lymphoma Society (LLS) has embarked on an extraordinary journey with the launch of the PedAL (Pediatric Acute Leukemia) Master Clinical Trial, a trailblazing effort that marks the world's first-ever global trial focused on menin inhibitors for treating pediatric leukemia. This initiative is part of LLS's broader...

Continue Reading
Aflac Partners with Workday to Enhance Employee Benefits Experience

Updated Category News Views 196

Aflac's Collaboration with Workday for Enhanced Wellness Solutions Aflac, a prominent provider of supplemental insurance in the U.S., has entered into a partnership with Workday Wellness aimed at revolutionizing employee benefit offerings. This strategic relationship empowers employers to provide a more personalized experience for their workforce, ultimately aimed at...

Continue Reading